ArticleCase reports in oncology
The Rare Trio: Concomitant Bone Marrow Involvement by Smoldering Myeloma and Systemic Mastocytosis with an Associated Hematologic Neoplasm and ALECT-2 Renal Amyloidosis - A Case Report and Literature Review.
Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Systemic mastocytosis (SM) is a clonal disorder characterized by abnormal accumulation of mast cells in various tissues and is categorized into distinct subtypes per the World Health Organization (WHO) 2022 classification. When SM is associated with another hematologic neoplasm, typically of myeloid lineage, it is classified as systemic mastocytosis with an associated hematologic neoplasm (SM-AHN). Coexistence with plasma cell dyscrasias is rare, with fewer than 15 published cases involving either smoldering multiple myeloma (SMM) or multiple myeloma (MM). ALECT-2 amyloidosis, a non-immunoglobulin-derived amyloid subtype, is typically isolated to the kidneys and has not been previously reported in context of SM-AHN. Case Presentation: We describe the first documented case of concurrent SMM, SM-AHN, and ALECT-2 amyloidosis in a 67-year-old male of Egyptian descent with stage 3B chronic kidney disease and proteinuria. Diagnostic workup revealed lambda-restricted plasma cell infiltration, KIT D816V-positive multifocal mast cell aggregates, and renal-limited ALECT-2 deposits confirmed by mass spectrometry. Serum immunofixation electrophoresis showed a monoclonal lambda free light-chain band without a corresponding intact heavy-chain M-protein, and serum protein electrophoresis showed no M-spike. The patient was managed with active surveillance, and the available records document approximately 24 months of follow-up. Conclusion: This case highlights the diagnostic and clinical implications of overlapping hematologic and renal disorders, underscores the role of proteomic amyloid typing in avoiding misdiagnosis, and explores potential pathogenic interplay between mast cells, plasma cells, and the marrow microenvironment. This case also underscores the importance for clinicians remaining vigilant and considers the possibility of non-AL amyloidosis, even when a plasma cell disorder diagnosis has been documented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.